IP Library Granted Patent US 9,932,378
Granted Patent B2
US 9,932,378 · App. 14/832,922 · Granted Apr 3, 2018

Regulators of NFAT

Inventors: Anjana Rao (Cambridge, MA); Stefan Feske (New York, MA); Patrick Hogan (Cambridge, MA); Yousang Gwack (Los Angeles, CA)
Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
C07K14/4702C07K16/18G01N33/5041A61K35/12C07H21/04C12N5/16C12N15/63C12N15/907C12N2510/00C12Q1/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,932,378
App. No.
14/832,922
Granted
Apr 3, 2018
Kind
B2
Abstract

Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein. Methods of identifying an agent that modulates intracellular calcium, methods to screen for an agent that modulates NFAT regulator function, methods to diagnose unexplained immunodeficiency in a subject, and methods for identifying an agent for treating or preventing a disease or disorder associated with a NFAT regulator protein or calcium signaling are also disclosed.

Claims (5)

1. A recombinant cell comprising a heterologous nucleic acid encoding at least one mammalian Nuclear Factor of Activated T cells (NFAT) regulator protein that is an orai polypeptide, wherein the heterologous nucleic acid is a mammalian NFAT regulator gene, wherein the NFAT regulator gene is ORAI1; and the recombinant cell is an isolated cell.

2. An isolated recombinant cell comprising a heterologous mammalian ORAI1 gene and a heterologous mammalian stromal interaction molecule (STIM) gene.

3. The recombinant cell of claim 2 , wherein the cell is an isolated, mammalian, human, rodent, insect, or Xenopus cell.

4. The recombinant cell of claim 3 , wherein the ORAI1 gene and the STIM gene are human nucleic acid sequences.

5. The recombinant cell of claim 3 , wherein the ORAI1 gene and the STIM gene are expressed in the cell to produce heterologous ORAI1 and heterologous stromal interaction molecule (STIM) polypeptides.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2017
From: RAO, ANJANA; FESKE, STEFAN; HOGAN, PATRICK; GWACK, YOUSANG
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 044404/0948 →
MERGER Recorded Dec 15, 2017
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 044405/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2017
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 044405/0129 →
Continuity (4)
Continuation 13161307 · Jun 15, 2011
Continuation 12160030
Provisional Application 60756934 · Jan 5, 2006
Related Publication 20160052981A1 · Feb 25, 2016